2026 Q1 -tulosraportti
26 päivää sitten
‧30 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 189 | - | - | ||
| 11 | - | - | ||
| 5 | - | - | ||
| 47 | - | - | ||
| 22 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 16.7. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 28.4. | ||
2025 Q4 -tulosraportti 5.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 16.7.2025 | ||
2025 Q1 -tulosraportti 6.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·2 päivää sittenGood answer from IR Orexo today on some questions I asked. Thanks for your email and interest in Orexo. We are continuously discussing, and that together with BARDA, a number of regulatory strategies as a way to shorten the development time and this also includes FDA's evaluation of the application. Fast track is one of several options that we will discuss with FDA. OX390 is currently the only product that addresses the growing problem with "Tranq" and we see good conditions for a constructive dialogue with FDA. We otherwise see a growing interest and recognition of the value of atipamezole, the active substance in OX390, for the treatment of overdose in the USA. The next advisory meeting with FDA is planned to take place in the current quarter. It is a so-called C-meeting with a focus on discussing the continued preclinical development of OX390. Good info from IR Lena at Orexo, BARDA is part OF FDA lives in the same building they have, as you know, invested almost 500 milj to OREXO for OX390 and given OREXO all future opportunities. No similar antidote exists in the world and USA, Pretty good odds for fast track and great interest from pharmaceutical companies in drug-related rescue medicines.- ·2 päivää sittenOX390 and Izipry are two completely unique rescue preparations for overdoses, competitors have only increased dose with naloxone which partly does not give a safe effect but also dangerous side effects. Orexo sits on two golden eggs that will be bought up in some form for great values, the share price will rise more and more the more this spreads in the market.
- ·19.5.OX390 An important step in the pipeline for OX390, it provides a basis for taking the first advisory contact with the FDA and for proceeding according to schedule. This also clears the way for continued release of capital from the BARDA support within the development. In addition, there is of course further evidence for the Amorpha platform's unique capabilities within nasal technology for drug delivery. Likely, ongoing agreements/partnerships or acquisitions concerning Izipry are now underway. When this happens, the stock will rise significantly and Orexo has secured a budget for many years to then go broad with the Amorph technology. The board is very qualified now and it likely steers the CEO with a tight rein, so I don't think the CEO question is decisive in the near future. A very interesting question during consultation with the FDA regarding OX390 is whether anything can be said about fast-tracking given the health crisis that OX390 is uniquely positioned to address with new technology today. Being able to buy this company at these levels will likely prove to be very good.
·6.5.Haven't owned orexo or even looked at its status for about a decade now. How can Nikolaj not have been fired?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
26 päivää sitten
‧30 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 päivää sittenGood answer from IR Orexo today on some questions I asked. Thanks for your email and interest in Orexo. We are continuously discussing, and that together with BARDA, a number of regulatory strategies as a way to shorten the development time and this also includes FDA's evaluation of the application. Fast track is one of several options that we will discuss with FDA. OX390 is currently the only product that addresses the growing problem with "Tranq" and we see good conditions for a constructive dialogue with FDA. We otherwise see a growing interest and recognition of the value of atipamezole, the active substance in OX390, for the treatment of overdose in the USA. The next advisory meeting with FDA is planned to take place in the current quarter. It is a so-called C-meeting with a focus on discussing the continued preclinical development of OX390. Good info from IR Lena at Orexo, BARDA is part OF FDA lives in the same building they have, as you know, invested almost 500 milj to OREXO for OX390 and given OREXO all future opportunities. No similar antidote exists in the world and USA, Pretty good odds for fast track and great interest from pharmaceutical companies in drug-related rescue medicines.
- ·2 päivää sittenOX390 and Izipry are two completely unique rescue preparations for overdoses, competitors have only increased dose with naloxone which partly does not give a safe effect but also dangerous side effects. Orexo sits on two golden eggs that will be bought up in some form for great values, the share price will rise more and more the more this spreads in the market.
- ·19.5.OX390 An important step in the pipeline for OX390, it provides a basis for taking the first advisory contact with the FDA and for proceeding according to schedule. This also clears the way for continued release of capital from the BARDA support within the development. In addition, there is of course further evidence for the Amorpha platform's unique capabilities within nasal technology for drug delivery. Likely, ongoing agreements/partnerships or acquisitions concerning Izipry are now underway. When this happens, the stock will rise significantly and Orexo has secured a budget for many years to then go broad with the Amorph technology. The board is very qualified now and it likely steers the CEO with a tight rein, so I don't think the CEO question is decisive in the near future. A very interesting question during consultation with the FDA regarding OX390 is whether anything can be said about fast-tracking given the health crisis that OX390 is uniquely positioned to address with new technology today. Being able to buy this company at these levels will likely prove to be very good.
- ·6.5.Haven't owned orexo or even looked at its status for about a decade now. How can Nikolaj not have been fired?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 189 | - | - | ||
| 11 | - | - | ||
| 5 | - | - | ||
| 47 | - | - | ||
| 22 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 16.7. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 28.4. | ||
2025 Q4 -tulosraportti 5.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 16.7.2025 | ||
2025 Q1 -tulosraportti 6.5.2025 |
2026 Q1 -tulosraportti
26 päivää sitten
‧30 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 16.7. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 28.4. | ||
2025 Q4 -tulosraportti 5.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 16.7.2025 | ||
2025 Q1 -tulosraportti 6.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 päivää sittenGood answer from IR Orexo today on some questions I asked. Thanks for your email and interest in Orexo. We are continuously discussing, and that together with BARDA, a number of regulatory strategies as a way to shorten the development time and this also includes FDA's evaluation of the application. Fast track is one of several options that we will discuss with FDA. OX390 is currently the only product that addresses the growing problem with "Tranq" and we see good conditions for a constructive dialogue with FDA. We otherwise see a growing interest and recognition of the value of atipamezole, the active substance in OX390, for the treatment of overdose in the USA. The next advisory meeting with FDA is planned to take place in the current quarter. It is a so-called C-meeting with a focus on discussing the continued preclinical development of OX390. Good info from IR Lena at Orexo, BARDA is part OF FDA lives in the same building they have, as you know, invested almost 500 milj to OREXO for OX390 and given OREXO all future opportunities. No similar antidote exists in the world and USA, Pretty good odds for fast track and great interest from pharmaceutical companies in drug-related rescue medicines.
- ·2 päivää sittenOX390 and Izipry are two completely unique rescue preparations for overdoses, competitors have only increased dose with naloxone which partly does not give a safe effect but also dangerous side effects. Orexo sits on two golden eggs that will be bought up in some form for great values, the share price will rise more and more the more this spreads in the market.
- ·19.5.OX390 An important step in the pipeline for OX390, it provides a basis for taking the first advisory contact with the FDA and for proceeding according to schedule. This also clears the way for continued release of capital from the BARDA support within the development. In addition, there is of course further evidence for the Amorpha platform's unique capabilities within nasal technology for drug delivery. Likely, ongoing agreements/partnerships or acquisitions concerning Izipry are now underway. When this happens, the stock will rise significantly and Orexo has secured a budget for many years to then go broad with the Amorph technology. The board is very qualified now and it likely steers the CEO with a tight rein, so I don't think the CEO question is decisive in the near future. A very interesting question during consultation with the FDA regarding OX390 is whether anything can be said about fast-tracking given the health crisis that OX390 is uniquely positioned to address with new technology today. Being able to buy this company at these levels will likely prove to be very good.
- ·6.5.Haven't owned orexo or even looked at its status for about a decade now. How can Nikolaj not have been fired?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 189 | - | - | ||
| 11 | - | - | ||
| 5 | - | - | ||
| 47 | - | - | ||
| 22 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt